Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senicapoc in Familial Dehydrated Stomatocytosis
NCT04372498Phase 2Completed
- Sponsor
- Boston Children's Hospital
- Start
- Apr 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of senicapoc in Dehydrated hereditary stomatocytosis (DHSt), sponsored by Boston Children's Hospital. Primary endpoint: chronic hemolysis biomarkers at 6 months. Started Apr 2021; status: completed.
02
Drugs
senicapoc
03
Conditions
Dehydrated hereditary stomatocytosis (DHSt)
Beyond the preview
Go deeper on NCT04372498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04372498.